D A Reardon

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma
    David A Reardon
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 118:4759-67. 2012
  2. ncbi request reprint Advances in malignant glioma drug discovery
    David A Reardon
    Duke University Medical Center, The Preston Robert Tisch Brain Tumor Center at Duke, Departments of Surgery and Pediatrics, Box 3624, Durham, NC 27710, US 1 919 668 2650 1 919 668 2485
    Expert Opin Drug Discov 6:739-53. 2011
  3. pmc Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 107:155-64. 2012
  4. ncbi request reprint Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:1389-97. 2002
  5. ncbi request reprint Recent advances in the treatment of malignant astrocytoma
    David A Reardon
    Preston Robert Tisch Brain Tumor Center at Duke University, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 24:1253-65. 2006
  6. ncbi request reprint Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents
    David A Reardon
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Oncologist 11:152-64. 2006
  7. ncbi request reprint Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma
    David A Reardon
    AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Clin Cancer Res 12:860-8. 2006
  8. ncbi request reprint Glioblastoma--more questions than answers?
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Nat Clin Pract Oncol 3:60-1. 2006
  9. ncbi request reprint Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC, 27710, USA
    J Clin Oncol 24:115-22. 2006
  10. pmc Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma
    David A Reardon
    Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 115:2188-98. 2009

Research Grants

Detail Information

Publications89

  1. pmc Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma
    David A Reardon
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 118:4759-67. 2012
    ..We evaluated the efficacy of imatinib plus hydroxyurea in patients with progressive/recurrent low-grade glioma...
  2. ncbi request reprint Advances in malignant glioma drug discovery
    David A Reardon
    Duke University Medical Center, The Preston Robert Tisch Brain Tumor Center at Duke, Departments of Surgery and Pediatrics, Box 3624, Durham, NC 27710, US 1 919 668 2650 1 919 668 2485
    Expert Opin Drug Discov 6:739-53. 2011
    ..Improved understanding of malignant glioma biology and factors associated with treatment response will probably lead to improved therapeutic options and a better patient outcome...
  3. pmc Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 107:155-64. 2012
    ..ClinicalTrials.gov number NCT00953121)...
  4. ncbi request reprint Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:1389-97. 2002
    ..To assess the efficacy and toxicity of intraresection cavity (131)I-labeled murine antitenascin monoclonal antibody 81C6 and determine its true response rate among patients with newly diagnosed malignant glioma...
  5. ncbi request reprint Recent advances in the treatment of malignant astrocytoma
    David A Reardon
    Preston Robert Tisch Brain Tumor Center at Duke University, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 24:1253-65. 2006
    ..The simultaneous development of multiple advanced therapies based on specific tumor biology may finally offer glioma patients improved survival...
  6. ncbi request reprint Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents
    David A Reardon
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Oncologist 11:152-64. 2006
    ..It is hoped that this combined approach will overcome the current limitations in the treatment of patients with GBM and result in a better prognosis for these patients...
  7. ncbi request reprint Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma
    David A Reardon
    AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Clin Cancer Res 12:860-8. 2006
    ....
  8. ncbi request reprint Glioblastoma--more questions than answers?
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Nat Clin Pract Oncol 3:60-1. 2006
  9. ncbi request reprint Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC, 27710, USA
    J Clin Oncol 24:115-22. 2006
    ..To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients...
  10. pmc Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma
    David A Reardon
    Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 115:2188-98. 2009
    ....
  11. doi request reprint Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme
    David A Reardon
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 26:5610-7. 2008
    ..The current multicenter phase II study was conducted to evaluate the activity and safety of cilengitide in GBM patients at first recurrence...
  12. ncbi request reprint Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
    J Nucl Med 47:912-8. 2006
    ....
  13. pmc Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme
    David A Reardon
    Duke University Medical Center, Neuro Oncology Program and Department of Surgery, Division of Neurosurgery, 047 Baker House, Box 3624, Durham, North Carolina, 27710, USA
    Expert Opin Investig Drugs 17:1225-35. 2008
    ..Integrins, widely expressed in GBM and tumor vasculature, mediate cell survival, migration and angiogenesis. Cilengitide is a potent alphavbeta3 and alphavbeta5 integrin inhibitor...
  14. pmc Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Neuro Oncol 10:330-40. 2008
    ..A subsequent phase 2 study is required to further evaluate the efficacy of this regimen for this patient population...
  15. pmc Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy
    David A Reardon
    Duke University Medical Center, Neuro Oncology Program, Department of Surgery, Division of Neurosurgery, 047 Baker House, Box 3624, Durham, North Carolina 27710, USA
    Expert Opin Biol Ther 8:541-53. 2008
    ..Malignant gliomas are amongst the most angiogenic of cancers, and VEGF is the dominant angiogenic mediator in these tumors...
  16. pmc A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:182-9. 2008
    ..S. Food and Drug Administration has approved a trial randomizing newly diagnosed GBM patients to either our study regimen or standard XRT plus temozolomide...
  17. doi request reprint The emerging role of anti-angiogenic therapy for malignant glioma
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Curr Treat Options Oncol 9:1-22. 2008
    ..Promising results of these approaches suggest that the treatment of GBM may represent an emerging paradigm of anti-angiogenic therapy...
  18. ncbi request reprint Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme
    David A Reardon
    Department of Medicine, Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Oncol 23:9359-68. 2005
    ....
  19. pmc Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 96:219-30. 2010
    ..029). Erlotinib plus sirolimus was well tolerated but had negligible activity among unselected recurrent GBM patients. (ClinicalTrials.gov number: NCT0062243)...
  20. pmc Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
    D A Reardon
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Br J Cancer 101:1995-2004. 2009
    ..We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs)...
  21. ncbi request reprint Irinotecan: promising activity in the treatment of malignant glioma
    David A Reardon
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Oncology (Williston Park) 17:9-14. 2003
    ..Other investigative directions include studies of irinotecan plus temozolomide and O6-benzylguanine (O6-BG) to assess the ability of O6-BG to maximize the therapeutic benefits of irinotecan combined with temozolomide...
  22. pmc Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma
    David A Reardon
    Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 106:409-15. 2012
    ..The only grade 3 or greater adverse event occurring in ≥ 10% of patients was anemia (10%). Imatinib plus hydroxyurea is well tolerated among patients with meningioma but has modest anti-tumor activity for this indication...
  23. pmc Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma
    David A Reardon
    Department of Pediatrics, Duke University Medical Center, Durham, NC, USA
    J Neurooncol 105:621-7. 2011
    ..The combination of sunitinib and irinotecan was associated with moderate toxicity and limited anti-tumor activity. Further studies with this regimen using the dosing schedules evaluated in this study are not warranted...
  24. pmc Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 6:134-44. 2004
    ..9 weeks for recurrent anaplastic astrocytoma/ anaplastic oligodendroglioma patients. We conclude that the activity of BCNU plus CPT-11 for patients with MG appears comparable to that of CPT-11 alone and may be more toxic...
  25. pmc Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 117:5351-8. 2011
    ..The efficacy of carboplatin, irinotecan, and bevacizumab among recurrent glioblastoma (GBM) patients after prior progression on bevacizumab therapy in a phase 2, open-label, single-arm trial was evaluated...
  26. pmc A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Natl Compr Canc Netw 9:414-27. 2011
    ..Better understanding of resistance mechanisms to VEGF inhibitors and identification of effective therapy after bevacizumab progression are currently a critical need for patients with glioblastoma...
  27. doi request reprint Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies
    David A Reardon
    Department of Surgery, Division of Neurosurgery, 047 Baker House, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Future Oncol 7:339-54. 2011
    ..Cilengitide is the first integrin inhibitor in clinical Phase III development for oncology...
  28. ncbi request reprint Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 103:329-38. 2005
    ..In the current study, the authors report a Phase II trial of irinotecan (CPT-11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX-2 inhibitor, among MG patients with recurrent disease...
  29. pmc Clinical trial end points for high-grade glioma: the evolving landscape
    David A Reardon
    The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Neuro Oncol 13:353-61. 2011
    ..Technical advances in imaging as well as improved survival for patients with HGG support the further development of auxiliary end points evaluating novel imaging approaches as well as measures of patient function and well being...
  30. pmc Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 103:371-9. 2011
    ..Alternative treatment strategies remain critically needed for this indication...
  31. pmc Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC, 27710, USA
    J Neurooncol 101:57-66. 2011
    ..In conclusion, sorafenib can be safely administered with daily temozolomide, but this regimen has limited activity for recurrent GBM. Co-administration of EIAEDs can lower sorafenib exposures in this population...
  32. pmc Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
    D A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Br J Cancer 101:1986-94. 2009
    ..We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial...
  33. ncbi request reprint Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 104:1478-86. 2005
    ..The authors determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan (CPT-11), a topoisomerase I inhibitor, when administered with temozolomide among patients with recurrent malignant glioma (MG)...
  34. ncbi request reprint Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
    Expert Rev Anticancer Ther 7:675-87. 2007
    ..This review summarizes clinical trials performed using radiolabeled antitenascin-C monoclonal antibodies for malignant glioma patients to date and highlights future plans to further develop this therapeutic strategy...
  35. pmc Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
    D A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 200 Trent Drive, Durham, NC 27710, USA
    Br J Cancer 107:1481-7. 2012
    ..We evaluated bevacizumab continuation beyond initial progression among recurrent glioblastoma patients as it is a common, yet unsupported practice in some countries...
  36. pmc Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy
    Jennifer A Quinn
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 95:393-400. 2009
    ..The lack of correlation of activity with MGMT expression is intriguing, but needs further evaluation in subsequent trials...
  37. pmc Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
    John H Sampson
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 28:4722-9. 2010
    ..Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms...
  38. ncbi request reprint Monoclonal antibodies for brain tumour treatment
    Abraham Boskovitz
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Expert Opin Biol Ther 4:1453-71. 2004
    ....
  39. pmc Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 115:2964-70. 2009
    ..The trial was designed to determine the maximum tolerated dose (MTD) and toxicity of irinotecan (CPT-11) when administered with temozolomide (TMZ) and O(6)-benzylguanine (O(6)-BG)...
  40. ncbi request reprint Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study
    Gamal Akabani
    Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA
    J Nucl Med 46:1042-51. 2005
    ....
  41. ncbi request reprint Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin
    John H Sampson
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    AJR Am J Roentgenol 188:703-9. 2007
    ..Our purpose was to test the hypothesis that hyperintense signal changes on T2-weighted images produced by such infusions can be used to track drug distribution...
  42. ncbi request reprint Neurofibromatosis type 2
    S Sathornsumetee
    Preston Robert Tisch Brain Tumor Center, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Neurology 68:E14. 2007
  43. pmc Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme
    Michael A Badruddoja
    Duke University Medical Center, Brain Tumor Center, Department of Surgery, Durham, NC 27710, USA
    Neuro Oncol 9:70-4. 2007
    ..Cloretazine administered every six weeks was relatively well tolerated, although this schedule has insignificant activity for patients with recurrent glioblastoma multiforme...
  44. doi request reprint Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy
    Mary Lou Affronti
    Department of Surgery, Duke University Medical Center, and The Preston Robert Tisch Brain Tumor Center, South Hospital, Durham, North Carolina 27710, USA
    Cancer 115:3501-11. 2009
    ..The effect of carmustine wafers on the survival of newly diagnosed GBM patients treated with radiotherapy (RT) and concurrent temozolomide (TMZ) plus RT plus rotational chemotherapy was investigated...
  45. pmc Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma
    Jennifer A Quinn
    Departments of Surgery, Duke University Medical Center, PO Box 3624, Durham, NC 27710, USA
    J Clin Oncol 27:1262-7. 2009
    ....
  46. pmc An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Mol Cancer Ther 8:2773-9. 2009
    ..7 months (C.I.(95), 14.5-25.6). Overall median survival from time of histologic diagnosis was 22.8 months (C.I.(95), 17.5-29). This study establishes the EGFRvIII mutation as a safe and immunogenic tumor-specific target for immunotherapy...
  47. ncbi request reprint Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC, USA
    J Clin Oncol 23:7178-87. 2005
    ..In addition, plasma concentrations of O6-BG and O6-benzyl-8-oxoguanine were evaluated after O6-BG...
  48. pmc Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients
    Stephanie L Perry
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 95:129-34. 2009
    ..Tinzaparin at a fixed prophylactic dose is safe and may decrease the incidence of thromboembolic complications in brain tumor patients...
  49. ncbi request reprint Chemotherapy and novel therapeutic approaches in malignant glioma
    Annick Desjardins
    The Brain Tumor Center, Department of Pediatrics, Duke University Medical Center, 047 Baker House, Trent Drive, Box 3624, Durham, NC 27710, USA
    Front Biosci 10:2645-68. 2005
    ..In this article, we review the past, present and future treatments of malignant gliomas with a special interest on chemotherapy, resistance mechanisms and tyrosine kinase inhibitors...
  50. ncbi request reprint ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors
    Jeremy N Rich
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 11:8145-57. 2005
    ..Current nonspecific therapies frequently have poor efficacy in many of these tumor types, so there is a pressing need for the development of novel targeted therapies...
  51. pmc Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma
    Lee W Jones
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 116:695-704. 2010
    ..The study was undertaken to evaluate cardiorespiratory fitness, skeletal muscle function, and body composition of patients with newly diagnosed and untreated, postsurgical primary malignant glioma...
  52. doi request reprint Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy
    Katherine B Peters
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, 27710, USA
    J Neurooncol 101:155-9. 2011
    ....
  53. ncbi request reprint Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:2277-83. 2002
    ....
  54. ncbi request reprint Phase II trial of temozolomide in patients with progressive low-grade glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 21:646-51. 2003
    ..We have extended these results, and now we report results of a phase II trial of Temodar for patients with progressive, low-grade glioma...
  55. ncbi request reprint Phase II trial of gefitinib in recurrent glioblastoma
    Jeremy N Rich
    Duke University Medical Center, Box 2900, Durham, NC 27710, USA
    J Clin Oncol 22:133-42. 2004
    ..To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma...
  56. ncbi request reprint Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant b
    John H Sampson
    Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 65:27-35. 2003
    ..9 weeks. Overall, 3 of 15 patients, with residual disease at the time of therapy, have demonstrated radiographic responses and one patient with a complete response and has survived greater than 83 weeks...
  57. pmc Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 6:145-53. 2004
    ....
  58. ncbi request reprint Kluver-Bucy syndrome related to glioma
    Michael A Badruddoja
    Duke University Medical Center, 5801 Genesee St, Durham, NC 27712, USA
    Neurology 63:184. 2004
  59. ncbi request reprint Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
    Ranjit K Goudar
    Department of Pathology, Duke University Medical Center, P O Box 2900, Durham, NC 27710, USA
    Mol Cancer Ther 4:101-12. 2005
    ..These studies suggest that simultaneous inhibition of growth factor receptor and mTOR pathways offer increased benefit in glioma therapy...
  60. pmc Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas
    Annick Desjardins
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:7068-73. 2008
    ..We did a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan for patients with recurrent grade 3 malignant glioma...
  61. ncbi request reprint Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme
    Chien Tsun Kuan
    Preston Robert Tisch Brain Tumor Center at Duke, Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA
    Clin Cancer Res 12:1970-82. 2006
    ....
  62. pmc Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
    Jennifer A Quinn
    Dept of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC, USA
    Neuro Oncol 11:556-61. 2009
    ..This study provides the foundation for a phase II trial of O(6)-BG in combination with a 5-day dosing schedule of TMZ in TMZ-resistant MG...
  63. ncbi request reprint Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
    Annick Desjardins
    Department of Medicine, Division of Neurology, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 83:53-60. 2007
    ..We performed the current phase 2 study to evaluate this regimen among patients with recurrent WHO grade III malignant glioma (MG)...
  64. pmc Temozolomide in children with progressive low-grade glioma
    Sridharan Gururangan
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Neuro Oncol 9:161-8. 2007
    ..TMZ given in this schedule was successful in stabilizing disease in a significant proportion of the patients with OPG/PA, with manageable toxicity...
  65. pmc Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Nucl Med Biol 34:405-13. 2007
    ....
  66. pmc Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Box 3050, Room 220 Sands Building, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:320-9. 2008
    ..However, the potential efficacy of drugs delivered by this technique may be severely constrained by ineffective infusion in many patients...
  67. ncbi request reprint Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
    James J Vredenburgh
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 25:4722-9. 2007
    ..We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan...
  68. doi request reprint Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma
    Richard G Everson
    Division of Neurosurgery, Department of Surgery, Box 3050 Med Ctr, Preston Robert Tisch Brain Tumor Center at Duke University, Durham, NC 27710, USA
    Expert Rev Anticancer Ther 8:717-32. 2008
    ....
  69. ncbi request reprint Exercise interest and preferences among patients diagnosed with primary brain cancer
    Lee W Jones
    Duke University Medical Center, Durham, NC 27710, USA
    Support Care Cancer 15:47-55. 2007
    ..Secondary aims were to examine potential differences in participant's interest and preferences by exercise behavior and select demographic/medical variables...
  70. pmc Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma
    Sridharan Gururangan
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:745-51. 2008
    ..The favorable impact of HDC on disease control in the two long-term survivors cannot be clearly established due to the cofounding effect of definitive RT postrecurrence...
  71. pmc Experience with irinotecan for the treatment of malignant glioma
    James J Vredenburgh
    The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 11:80-91. 2009
    ..Toxicities associated with irinotecan have been manageable; the most important dose-limiting toxicities are neutropenia and diarrhea. Irinotecan-based chemotherapy of malignant glioma merits further study...
  72. ncbi request reprint Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
    James J Vredenburgh
    The Preston Robert Tisch Brain Tumor Center and Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 13:1253-9. 2007
    ..This study was conducted to determine if the combination of a novel antiangiogenic therapy, bevacizumab, and a cytotoxic agent, irinotecan, is safe and effective for patients with recurrent grade III-IV glioma...
  73. pmc Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6
    Michael R Zalutsky
    Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Nucl Med 49:30-8. 2008
    ..The main goal of this study was to investigate the feasibility and safety of this approach in patients with recurrent malignant brain tumors...
  74. doi request reprint Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing
    Lee W Jones
    Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 94:79-85. 2009
    ..We conducted a pilot study to explore the feasibility and clinical utility of functional capacity testing to assess physical functioning in recurrent primary malignant glioma patients...
  75. pmc Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies
    Michael R Zalutsky
    Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA
    Nucl Med Biol 34:779-85. 2007
    ..Nonetheless, two clinical trials have been initiated to date with 211At-labeled mAbs, and others are planned for the near future...
  76. doi request reprint Poor drug distribution as a possible explanation for the results of the PRECISE trial
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University, Durham, North Carolina, USA
    J Neurosurg 113:301-9. 2010
    ..The purpose of the present work was to retrospectively analyze the expected drug distribution based on catheter positioning data available from the CED arm of the PRECISE trial...
  77. pmc Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions
    John H Sampson
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 9:343-53. 2007
    ..6% of catheters. Routine use of this algorithm, and its further developments, should improve prospective selection of catheter trajectories, and thereby improve the efficacy of drugs delivered by this promising technique...
  78. ncbi request reprint Patterns of exercise across the cancer trajectory in brain tumor patients
    Lee W Jones
    Department of Surgery Neuro Oncology, Duke University Medical Center, Durham, North Carolina 27705, USA
    Cancer 106:2224-32. 2006
    ..Given the limited evidence, the authors conducted a survey to examine the exercise patterns of brain tumor patients across the cancer trajectory...
  79. pmc Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study
    John H Sampson
    Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 7:90-6. 2005
    ..This report describes a dramatic and sustained clinical and radiographic response in a patient with a bifrontal glioblastoma multiforme treated with intratumoral infusion of a novel targeted toxin, TP-38...
  80. pmc Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme
    Jennifer A Quinn
    Department of Surgery, Pathology, Biostatistics, and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 15:1064-8. 2009
    ....
  81. pmc Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study
    Lee W Jones
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Oncologist 15:636-47. 2010
    ..To investigate the feasibility of longitudinal assessment of functional performance measures in newly diagnosed postsurgical malignant glioma patients...
  82. ncbi request reprint Using the theory of planned behavior to understand the determinants of exercise intention in patients diagnosed with primary brain cancer
    Lee W Jones
    Duke University Medical Center, Durham, NC 27710, USA
    Psychooncology 16:232-40. 2007
    ..Information gained from this study suggests that the TPB is a useful framework to design and implement theoretically based interventions to promote exercise in primary brain cancer patients...
  83. pmc Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma
    M J Paldino
    Duke University Medical Center, Department of Radiology, Durham, NC 27710, USA
    Br J Radiol 84:327-33. 2011
    ....
  84. pmc Everolimus tablets for patients with subependymal giant cell astrocytoma
    Scott G Turner
    Duke University Medical Center, The Preston Robert Tisch Brain Tumor Center, Department of Surgery, Box 3624, Durham, NC 27710, USA
    Expert Opin Pharmacother 12:2265-9. 2011
    ..Recently, mTOR inhibitors such as everolimus have shown encouraging benefit for patients with SEGAs...
  85. ncbi request reprint Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma
    David N Korones
    James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Cancer 97:1963-8. 2003
    ..Temozolomide may prove more effective in combination with other agents. Therefore, combination oral chemotherapy for these patients is a particularly attractive approach...
  86. ncbi request reprint Diagnosis and treatment of high-grade astrocytoma
    Sith Sathornsumetee
    Division of Neurology, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, DUMC 3624, Durham, NC 27710, USA
    Neurol Clin 25:1111-39, x. 2007
    ..It is probable that targeted therapies will be most effective in combination with one another or with cytotoxic therapies. This article discusses diagnosis and current treatment of high-grade astrocytomas...
  87. ncbi request reprint 3'-Deoxy-3'-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging
    Yuka Yamamoto
    Department of Radiology, Nuclear Medicine Division, Duke University Medical Center, Durham, NC, USA
    Mol Imaging Biol 8:340-7. 2006
    ....
  88. ncbi request reprint Molecularly targeted therapy for malignant glioma
    Sith Sathornsumetee
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 110:13-24. 2007
    ..In this review, the authors discussed the current understanding of molecular pathogenesis and the development of molecularly targeted therapies in malignant glioma...
  89. pmc A review of micro- and macrovascular analyses in the assessment of tumor-associated vasculature as visualized by MR
    Elizabeth Bullitt
    CASILab, CB 7062, University of North Carolina, Chapel Hill, NC 27599, USA
    Neuroimage 37:S116-9. 2007
    ..The two approaches provide different, complementary information and together could provide important insights into cancer growth as well as new methods of assessing malignancy and tumor treatment response...

Research Grants1

  1. Phase II Study of 44Gy from 131I-81C6 for CNS Tumors
    David Reardon; Fiscal Year: 2004
    ..To further define the toxicity of this approach and Specific Aim 3.To determine the impact of this therapy on quality of life. ..